Table 2.
Model | Fat Intervention/s | Muscle Lipid Change | Glucose Uptake/Insulin Resistance | Reference |
---|---|---|---|---|
L6 myotubes | PA, LA, DHA at 0.4 mmol/L | Muscle DAG: | Muscle glucose uptake: | [45] |
| ||||
|
|
|||
|
|
|||
|
|
|||
Muscle Ceramide (in presence of PA): | Myriocin inhibits ceramide synthesis | |||
|
DHA increases hydrolysis of sphingomyelin | |||
| ||||
L6 myotubes | Palmitic acid (Palmitate), Linoleic acid (Linoleate) | Muscle DAG: | Muscle glucose uptake: | [53] |
| ||||
| ||||
0.5 mmol/L | Muscle Ceramide: |
|
||
|
Unaffected by LA | |||
| ||||
C12C12 myotubes | Normal FA mixture (40% SFA), high SFA FA mixture (60% SFA) & 100% Palmitic acid | Muscle DAG: | Akt phosphorylation impaired (p < 0.05) by 100% PA. | [54] |
Doses: 0.1, 0.2, 0.4 or 0.8 mmol/L |
|
Modest impact of the two mixtures. No difference between 40% & 60% SFA. | ||
| ||||
Vastus lateralis biopsies (Obese non-diabetic men & women) | Normal FA mixture (40% SFA), high SFA FA mixture (60% SFA) & 100% Palmitic acid | Muscle DAG: | Akt phosphorylation impaired (p > 0.05) by 100% PA. | [54] |
Dose: 0.4 mmol/L |
|
Modest impact of the two mixtures. No difference between 40% & 60% SFA. |
DAG, diacylglycerol; DHA, docosahexaenoic acid; FA, fatty acid; LA, linoleic acid; PA, palmitic acid; SFA, saturated fatty acid.